Open Access

Table 2

The relationship between the presence of integrons and resistance to antibiotics in clinical isolates of Pseudomonas aeruginosa in the present study.

All isolates (n = 200) Integron positives (n = 55) Integron negatives (n = 145)

Antibiotics R* I* S* R* I* S* R* I* S* P value**
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Amikacin 110 9 81 34 2 19 79 3 63 NS*
(55) (4.5) (40.5) (61.8) (3.6) (34.5) (54.4) (2) (43.4)
Cefepime 125 0 75 36 0 19 89 0 56 NS
(62.5) (37.5) (65.4) (34.5) (61.3) (38.6)
Ceftazidime 113 0 67 40 0 15 93 0 52 NS
(66.5) (33.5) (72.7) (27.2) (64.1) (33.8)
Tobramycin 115 0 85 26 0 29 86 0 59 NS
(57.5) (42.5) (47.2) (52.7) (59.3) (40.6)
Gentamicin 124 0 76 39 0 16 85 0 60 NS
(62) (38) (70.9) (29) (58.9) (41.3)
Imipenem 93 12 95 25 3 17 73 5 67 NS
(46.5) (6) (47.5) (45.4) (5.4) (30.9) (50.3) (3.4) (46.2)
Colistin 6 0 194 2 0 53 4 0 141 NS
(3) (97) (3.6) (96.3) (2.7) (97.2)
Ciprofloxacin 125 0 75 33 0 22 88 0 57 NS
(62.5) (37.5) (60) (40) (60.6) (39.3)
Amoxicillinclavulanate 121 0 79 33 0 22 86 0 59 NS
(60.5) (39.5) (60) (40) (59.3) (40.6)
Cefotaxime 149 3 48 39 1 15 109 2 34 NS
(74.5) (1.5) (24) (70.9) (1.8) (27.2) (75.1) (1.3) (23.4)
Ceftazidimeclavulanate 110 0 90 33 0 22 77 0 68 NS
(55) (45) (60) (40) (53.1) (46.8)
*

R: resistant. I: intermediate. S: susceptible. NS: not statistically significant.

**

Statistical analysis was done by Chi-square method using SPSS software. All other statistical analysis were done by descriptive methods.

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.